CA-CONVIVA
4.11.2021 17:02:13 CET | Business Wire | Press release
Despite predictions of a ”pandemic peak,” streaming adoption continues to gain ground in almost every single region quarter after quarter, according to the Q3 2021 State of Streaming report from Conviva, the continuous measurement platform for streaming media. Streaming viewing time grew 21% worldwide in Q3 2021 as compared to the same quarter in 2020, led by Africa, Oceania and South America while North America, an established streaming market, held steady with the most modest growth of any region, up just 2%.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211104005139/en/
“Streaming viewing has grown 266% over the past three years, completely transforming the entertainment, publishing and advertising industries,” said Keith Zubchevich, CEO, Conviva. “Topics like quality of experience, advertising measurement and social engagement are now top of mind and the publishers that effectively leverage opportunities to improve in these areas will not only lead the industry in subscribers and viewer satisfaction, but also revenue.”
The report also found streaming publishers investing heavily in video content on social media platforms in Q3 2021 – especially YouTube – in order to test new content and promote their catalog with viewers. In fact, streaming platforms increased their content output on YouTube by 97%, which resulted in an 8.4% increase in views and a 24% increase in engagement. Audiences for streaming platform accounts grew by 66% on YouTube in Q3 2021 as compared to Q3 2020.
Buffering Nearly Eliminated; Higher Quality = Higher Engagement
Q3 2021 marks the first quarter all regions experienced sub-1% buffering, with buffering seeing the largest improvements in more nascent regions like Africa, down 78% year over year. North America had the most modest gains over last year, with a 29% reduction in buffering, which was enough to maintain its position as the region with the least buffering at just 0.19%. Year over year, picture quality also made gains with bitrate improving in every region.
Higher quality delivered higher consumer engagement across the board. When buffering rates were less than 0.4%, viewers engaged for an average of 28.44 minutes in Q3, with that steadily declining with each incremental increase in buffering. Similarly, higher picture quality correlated with higher engagement as viewers averaged more than 20 minutes at bitrates above 3.5 Mbps in Q3 with engagement declining as bitrates dropped.
Big screen domination persisted
Despite seeing a slight decrease in share over Q3 of last year, big screens – which includes connected TV devices, smart TVs and gaming consoles – still accounted for almost three quarters (73%) of viewing time worldwide. Roku, Amazon Fire TV and Samsung TV made up the bulk of big screen viewing time globally with Roku again coming out on top with 31.1% share. Amazon Fire TV fell from 20% in Q3 2020 to 16.8% in Q3 2021, while Samsung gained nearly 3 percentage points over Q3 of last year going from 9.4% to 12.2% share of global viewing time. LG TV, Android TV, Apple TV and Chromecast also gained share over last year.
In every part of the world except Asia, big screens were the majority of viewership, particularly in North America with 82%. Mobile phones, desktops and tablets barely registered in North America at 8%, 6% and 4%, respectively.
Advertising continues advances in streaming
Streaming advertising made significant gains in Q3 2021. Ad attempts and ad impressions were up over 30% in Q3 2021, as compared to Q2 2021. Just 15% of ads in Q3 2021 were not delivered as intended, for a 23% decrease in missed ad opportunities quarter over quarter. Ad duration decreased by 3% from last quarter to 26 seconds, satisfying consumer requests for shorter ad breaks. Advertising quality was a mixed bag in Q3 2021, as ad buffering worsened by 22% and picture quality decreased 1% from last quarter.
Download the full report here .
Methodology
Conviva’s data is primarily collected using proprietary sensor technology with a global footprint of more than 500 million unique viewers watching 180 billion streams per year across nearly 4 billion applications streaming on devices. Embedded directly within streaming video applications, the sensor measures across content and ads to analyze nearly three trillion real-time transactions per day for its customers. In the State of Streaming report, the year-over-year data from Q3 2021 as compared to Q3 2020 was normalized based on Conviva’s customer base. The social media data consists of data from over 2800 accounts, over 21 million posts, and over 18 billion engagements across Facebook, Instagram, Twitter, and YouTube in Q3 2021.
About Conviva
Conviva is the census, continuous measurement and engagement platform for streaming media. Powered by our patented Stream Sensor™ and Stream ID™, our real-time platform enables marketers, advertisers, tech ops, engineering and customer care teams to acquire, engage, monetize and retain their audiences. Conviva is dedicated to supporting brands like CCTV, DAZN, Disney+, Hulu, Paramount+, Peacock, Sky, Sling TV, TED and WarnerMedia as they unlock the incredible opportunity in streaming media. Today our platform processes nearly 3 trillion streaming data events daily, supporting more than 500 million unique viewers watching 200 billion streams per year across 4 billion applications streaming on devices. Conviva ensures digital businesses of all sizes can stream better—every stream, every screen, every second. To learn more, visit www.conviva.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211104005139/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release
SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
